<\/b><\/p>\n
<\/b><\/p>\n
FRIDAY, June 15, 2018 (HealthDay News) — Elevated baseline N-terminal B-type natriuretic peptide (NT-proBNP) is independently associated with development of major cardiovascular (CV) events, in particular hospitalization for heart failure, according to a study published online May 30 in Diabetes Care<\/i>.<\/p>\n
Petr Jarolim, M.D., Ph.D., from Brigham and Women’s Hospital in Boston, and colleagues examined the prognostic implications of changes in NT-proBNP concentration in patients with type 2 diabetes and ischemic heart disease enrolled in the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trial. Eligible patients had type 2 diabetes and a recent acute coronary syndrome event.<\/p>\n
The researchers identified a strong graded correlation between increasing baseline and six-month NT-proBNP concentration and the incidence of major CV events. NT-proBNP at baseline was independently linked to development of major CV events, in particular hospitalization for heart failure, after adjustment for potential confounders. Compared to patients in whom NT-proBNP remained low at both time points or who had a high NT-proBNP at baseline that subsequently declined, individuals with persistently high NT-proBNP or those who developed high NT-proBNP at six months were at significantly higher risk for CV death\/heart failure.<\/p>\n
“Serial monitoring of NT-proBNP in patients with type 2 diabetes and ischemic heart disease may be useful for identifying patients at highest risk for heart failure,” the authors write.<\/p>\n
Several authors disclosed financial ties to pharmaceutical companies, including the Takeda Global Research and Development Center, which supported the trial.<\/p>\n
Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n